Literature DB >> 3910053

Study of the long-term action of a Ginkgo biloba extract on vigilance and mental performance as determined by means of quantitative pharmaco-EEG and psychometric measurements.

B Gessner, A Voelp, M Klasser.   

Abstract

The action of a Ginkgo biloba extract (rökan, Tanakan, G.B.E.) in promoting blood flow has been demonstrated in several animal and human pharmacological studies. The aim of this present study was to estimate the action of the substance on the central nervous system in order to be able to assess its potential use as a therapeutic agent in geriatric patients with cerebral insufficiency. Quantitative pharmaco-EEG is the method of choice for studying the vigilance-promoting effects of a drug. It is incomparable for confirming the findings of behavioural and psychometric studies. 60 volunteers of either sex participated in the double-blind trial. They were aged 57-77 years and showed mental deterioration corresponding to their age. They were randomly divided into three experimental groups: 20 subjects received 3 X 40 mg/day G.B.E., 20 received 5 mg nicergoline and 20 received a placebo of similar appearance. The subjects underwent an extensive series of examinations before and 4, 8 and 12 weeks after the start of medication. Analysis of the EEG results for the whole group revealed no significant advantage of G.B.E. over the two reference substances with regard to vigilance. However, a subclassification of the subjects showed that the vigilance of those persons with a more unfavourable initial situation measured in the resting EEG could be clearly improved by chronic G.B.E. medication. This increase in vigilance was reflected at the behavioural level by an improvement of reaction times in the G.B.E. group by comparison with the reference substances.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3910053

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  10 in total

Review 1.  Complementary and alternative medicines in the treatment of dementia: an evidence-based review.

Authors:  Bruce Diamond; Susan Johnson; Kathleen Torsney; Jennifer Morodan; Brian Prokop; Dana Davidek; Patricia Kramer
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 2.  Botanical and dietary supplements for menopausal symptoms: what works, what does not.

Authors:  Stacie E Geller; Laura Studee
Journal:  J Womens Health (Larchmt)       Date:  2005-09       Impact factor: 2.681

Review 3.  Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment.

Authors:  M Fioravanti; L Flicker
Journal:  Cochrane Database Syst Rev       Date:  2001

4.  Differential cognitive effects of Ginkgo biloba after acute and chronic treatment in healthy young volunteers.

Authors:  Sarah Elsabagh; David E Hartley; Osama Ali; Elizabeth M Williamson; Sandra E File
Journal:  Psychopharmacology (Berl)       Date:  2005-03-01       Impact factor: 4.530

5.  The in vivo neuromodulatory effects of the herbal medicine ginkgo biloba.

Authors:  C M Watanabe; S Wolffram; P Ader; G Rimbach; L Packer; J J Maguire; P G Schultz; K Gohil
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-29       Impact factor: 11.205

Review 6.  Ginkgo biloba for cerebral insufficiency.

Authors:  J Kleijnen; P Knipschild
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

7.  The comprehensiveness of Medline and Embase computer searches. Searches for controlled trials of homoeopathy, ascorbic acid for common cold and ginkgo biloba for cerebral insufficiency and intermittent claudication.

Authors:  J Kleijnen; P Knipschild
Journal:  Pharm Weekbl Sci       Date:  1992-10-16

8.  Ginkgolic Acid Protects against Aβ-Induced Synaptic Dysfunction in the Hippocampus.

Authors:  Dalila Mango; Filippo Weisz; Robert Nisticò
Journal:  Front Pharmacol       Date:  2016-10-26       Impact factor: 5.810

9.  Evaluation of ginkgo biloba extract on hematological changes affected with hazards of electromagnetic field exposure.

Authors:  H E Abdel Baieth
Journal:  Int J Biomed Sci       Date:  2009-09

Review 10.  A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline.

Authors:  Mario Fioravanti; Taku Nakashima; Jun Xu; Amit Garg
Journal:  BMJ Open       Date:  2014-07-30       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.